Bengaluru, Sept. 25 -- The shares of one of the pharmaceutical company, specializing in a broad range of pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients (APIs), jumped by upto 2 percent upon receiving U.S. FDA Approval for manufacturing HIV Treatment Tablets.

With a market capitalization of Rs. 91,924.13 crores on Thursday, the shares of Lupin Limited rose by upto 2.1 percent, making a high of Rs. 2034.95 per share compared to its previous closing price of Rs. 1991.20 per share.

What happened Lupin Limited, engaged in a broad range of pharmaceutical products, including branded and generic formulations, complex generics, biotechnology pro...